Falsified Medical Products in Francophone Sub-Saharan Africa

By Staff Writer

October 9, 2023

The Challenges of Substandard Medical Products

Substandard and falsified (SF) medical products pose a significant threat to public health. These products can cause harm, fuel resistance to genuine treatments, and undermine health systems. In Francophone sub-Saharan Africa, SF products are increasingly prevalent, largely due to the limited capacity of National Regulatory Authorities (NRAs) to fulfil their functions.

Solutions and Initiatives

Several initiatives are helping to combat this issue. The African Union (AU) and the World Health Organization (WHO) have launched the African Medicine Regulatory Harmonization (AMRH) Initiative and the African Medicines Agency (AMA). These initiatives aim to strengthen regulation and supply of quality-assured medical products.

The WHO Member State Mechanism is another important initiative, focusing on tackling SF medical products from a public health approach. Unfortunately, no NRAs in French-speaking Africa have yet achieved a maturity level 3. This indicates a stable, well-functioning, and integrated regulatory system. However, Burkina Faso, Niger, Ivory Coast, and Senegal are actively engaged in this process and could progress rapidly.

Academia also plays a crucial role in combating SF medical products. Universities like the University of Senegal Cheikh Anta Diop and the University of Douala in Cameroon have implemented a curriculum guide on SF medical products, educating future specialists and policymakers.

Procurement agencies, such as the Ecumenical Pharmaceutical Network (EPN), have also engaged in surveillance of SF medical products, integrating their data with national post-marketing surveillance of NRAs.

In conclusion, preventing, detecting, and responding to SF medical products remains a challenge in Francophone sub-Saharan Africa. However, through collective efforts and initiatives, progress is being made.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.